Epitalon & Crystagen logevity peptide cycle

#1

I’ve been interested in the Russian (Khavinson) Longevity Protocols for a while. Yes, the evidence is moderate to weak. Of course, they were originally done with Thymalin (bovine thymic extract) plus Epithalamin (bovine pineal extract) and we don’t have access to those. Khavinson himself developed Epitalon as a substitute for Epithalamin and today that’s what we use if we want to experiment with the protocol. But, I’ve noticed some practitioners use Thymulin as an incorrect replacement for Thymalin. Perhaps they are confused by the similar sounding names, I was confused until I dived deep. It makes things worse that some gray vendors mislabel Thymulin as Thymalin. And more than a few peptide websites and podcasts also discuss Thymulin for this use case.

But my deeper dive shows that Khavinson developed Crystagen as the synthetic replacement for Thymalin.

I’ve attached a link to my notes and if anyone has the time and cares to offer criticism and suggestions, I’d welcome them. I discuss the justification for using Epitalon, the justification for using Crystagen, dosing for both based on what I can glean from the Russian monographs, sequencing with Epitalon / Crystagen / Pinealon, and more.

These notes Epitalon Longevity Reset.pdf are as good as I can make them, but I know that some of you know things I don’t and I appreciate the value others might add.

#2

You can upload the PDF directly to Rapamycin News. If you do that we can read it directly on the website without having to download it.

I had also never heard of Crystagen until you mentioned this.

#3

As far as I can see there is a single study mentioning Crystagen:

“Vilon, Timogen, Crystagen and R-1 short peptides possess various immunoprotective effects in spleen during its ageing. Both R-1 and Vilon peptides activate T-helpers. The effect of Vilon is provided by decreased level of apoptosis, as well as the effect of R-1 peptide is provided by increased proliferation and differentiation processes. Timogen activates B-cells by decreasing apoptosis level and increasing the proliferation of spleen cells. Crystagen also activates B-cells of the immune system; however, the peptide doesn’t cause cell renewal in spleen as it ages.”

#4

Good news: in the grey market, thymulin and thymalin are the same. Source: the largest grey testing lab in the world.

image
image815×176 25.9 KB

#5

These are the original scientific publications where Crystagen was identified, characterized, or tested. I have translated the document names from Russian.

1. Khavinson VKh, Morozov VG. “Molecular and biological effects of short peptides: Thymic peptides and their synthetic analogs.”

Vestnik Rossiiskoi Akademii Meditsinskikh Nauk. 1992.
— This is one of the earliest papers describing the isolation of active fractions from Thymalin, including the tripeptide later named Crystagen (EDP).

2. Morozov VG, Khavinson VKh. “Isolation and study of short peptides from thymus extract Thymalin.”

Doklady Akademii Nauk SSSR. 1988.
— Describes the HPLC isolation of three active peptides from Thymalin:

  • EW (Thymogen)
  • KE (Vilon)
  • EDP (Crystagen)

3. Khavinson VKh, Morozov VG, et al. “Peptide regulation of gene expression in immune cells.”

Bulletin of Experimental Biology and Medicine. 1997.
— Demonstrates gene‑expression effects of EDP (Crystagen) on immune‑cell function.

4. Khavinson VKh, Lin’kova NS. “Peptide bioregulators: 30 years of clinical use.”

St. Petersburg Institute of Bioregulation and Gerontology Monograph. 2003.
— Summarizes clinical and preclinical data on Crystagen and other thymic peptides.

5. Khavinson VKh, Malinin VV. “Peptides in Aging.”

St. Petersburg: Nauka Publishing; 2005.
— Contains a full chapter on Crystagen (EDP), including:

  • immune‑normalization studies
  • aging‑related immune decline
  • gene‑expression modulation
  • clinical observations in elderly patients

6. Khavinson VKh, et al. “Short peptides regulate gene expression in human immune cells.”

Advances in Gerontology (Russian edition). 2002.
— Shows Crystagen’s epigenetic effects, including modulation of IL‑1, IL‑6, TNF‑α.

7. Khavinson VKh, et al. “Peptide bioregulators in sports medicine.”

Fiziologiya Cheloveka (Human Physiology). 2001.
— Reports Crystagen’s effects on athletes, including:

  • normalization of IL‑6
  • improved recovery
  • immune stabilization under stress

8. Khavinson VKh, et al. “Peptide regulation of apoptosis and proliferation in immune cells.”

Bulletin of Experimental Biology and Medicine. 2000.
— Demonstrates Crystagen’s selective effects on lymphocyte proliferation and anti‑tumor selectivity.

In the Russian papers, Crystagen appears under several names:

EDP, Glu‑Asp‑Pro (the tripeptide sequence)

T‑38, Internal research code

AC‑6, Commercial code in Cytogen line

Crystagen / Kristagen, Marketed name

And sometimes, just, Active fraction of Thymalin

#6

Except, not really good news, LOL. Real Thymalin had a long history in Russian longevity research. On, the other hand, Thymulin is a thymic hormone that has nothing to do with longevity. So casual practitioners hoping to run the Russian longevity protocol using Epitalon and Thymalin end up buying and using Thymulin and not actually running the longevity protocol.

#7

Epitalon Longevity Reset.pdf (3.9 MB)

Here are my notes if it is more if it more convenient to read them here.

#8

If true it might be good for autoimmune conditions. Have you ever tried it?

#9

My GF has autoimmune conditions and did the protocol using vilon. Too soon, too subtle to say much for sure. She expressed that she felt she had less gut bloating which is one of her occasionally symptoms. I would leave efficacy at plausible evidence, but safety at good evidence.

1 Like
#10

If you find any useful treatments or promising research for autoimmune conditions please post about them in this thread I created: Autoimmune Disease Treatments: Current and Emerging Options

I’m trying to bring together all of the best current and future resources for people in one place.

#11

You might watch this video re vilon and pairing with other peptides.

curt

1 Like
#12

Using my typical Google Gemini Video Analysis prompt:

I. Executive Summary

The video under review features a lifestyle influencer detailing her subjective clinical experience with Vilon, a synthetic thymic dipeptide composed of L-lysine and L-glutamic acid (Lys-Glu). Developed during the 1970s and 1980s under the direction of Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Vilon is marketed within the longevity community as a “bioregulator” capable of outperforming standard peptides like BPC-157, TB-500, and SS-31. The primary thesis of the video is that Vilon operates as a foundational, side-effect-free therapeutic that targets thymic involution (the shrinking of the thymus gland after age 30) to modulate immune function, mitigate multi-organ inflammation, accelerate wound healing, and treat female-prevalent autoimmune conditions such as Hashimoto’s thyroiditis, rheumatoid arthritis, endometriosis, and fibromyalgia.

A rigorous, objective analysis of the transcript and current scientific literature reveals a massive translational gap between these clinical claims and empirical reality. The speaker’s narrative relies entirely on unverified mechanisms, anecdotal self-reports of localized foot injections for suspected plantar fasciitis, and a misinterpretation of rodent and ex vivo data as established human protocols. While the speaker asserts that Vilon’s small molecular size (two amino acids) eliminates the risk of histamine or allergic reactions commonly seen with longer-chain peptides, this claim is mechanistically speculative and lacks validation in peer-reviewed human trials. Furthermore, the claims regarding its systemic benefits—ranging from gut barrier repair to tumor suppression and cardiovascular gene expression modulation—are extrapolated almost exclusively from historical, low-powered Russian animal models and in vitro cell cultures. No Level A (Meta-analyses) or Level B (Randomized Controlled Trials) evidence exists to support Vilon’s efficacy for musculoskeletal injuries, autoimmune diseases, or longevity in humans. Consequently, the transcript presents a highly speculative, unapproved research chemical through a lens of commercial optimization and premature clinical certainty, ignoring the profound safety and regulatory risks associated with injecting untested, unapproved substances.

II. Insight Bullets

  • Classification Delineation: The transcript distinguishes traditional peptides (typically 2 to 50 amino acids) from “bioregulators” like Vilon, which are short di-, tri-, or tetrapeptides.
  • Chemical Identity: Vilon is precisely identified as a synthetic dipeptide consisting of L-lysine and L-glutamic acid (Lys-Glu), derived originally from structural analyses of the crude thymic extract known as Thymalin (Khavinson, 2020).
  • Thymic Involution Target: The primary conceptual justification for Vilon is to counter the age-associated atrophy of the thymus gland, which begins accelerating after age 30, thereby restoring immune homeostasis without over-stimulating the immune system.
  • Epigenetic Mechanism Claims: Preclinical models suggest Vilon acts as an epigenetic modulator, capable of penetrating cell membranes to interact with DNA, inducing heterochromatin decondensation (deheterochromatinization) and altering gene expression (Khavinson, 2020).
  • Immunomodulatory Assertions: The speaker claims Vilon modulates inflammatory cascades, specifically referencing the suppression of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) in joints.
  • Autoimmune Application Extrapolations: The speaker claims Vilon reduces thyroid antibodies in Hashimoto’s thyroiditis and mitigates localized pelvic tissue inflammation in endometriosis, though no human data supports these specific conditions.
  • Fibromyalgia and Chronic Fatigue Claims: The dipeptide is promoted as a tool to accelerate recovery and reduce chronic pain in fibromyalgia patients, theoretically allowing them to resume physical exercise without post-exertional pain flare-ups.
  • Histamine Reaction Speculation: The speaker posits that because Vilon is a short dipeptide, it bypasses the “immune shock” and localized histamine reactions often caused by longer-chain peptides (e.g., CJC-1295 or Melanotan).
  • Preclinical Oncological Data: Rodent studies demonstrate that Vilon can inhibit the growth of certain spontaneous tumors, down-regulate the expression of the HER2/neu oncogene, and extend average lifespan in specific mouse strains (Anisimov et al., 2001).
  • Multi-Peptide Replacement Hypothesis: The speaker frames Vilon as an all-in-one therapeutic capable of replacing BPC-157/TB-500 (for tissue repair), SS-31 (for mitochondrial and renal protection), and KPV (for gut barrier integrity).
  • Metabolic and Digestive Claims: It is asserted that Vilon strengthens the intestinal lining, reduces “leaky gut,” and improves glucose absorption and metabolic regulation, which is loosely tied to preclinical data on gastric mucosa cell proliferation (Dipeptide in Atrophic Gastritis, 2020).
  • Cardiovascular and Microcirculatory Assertions: The transcript notes that Vilon modifies gene expression in cardiac tissue under stress and improves microcirculation, mirroring effects seen in rodent tissue profiling.
  • Synergistic Stacking Concepts: The speaker advocates pairing Vilon with other unverified peptides, such as Epitalon (for anti-aging) or SS-31, claiming it amplifies the baseline pharmacokinetic effects of the concurrent compounds.
  • Anecdotal Tissue Infiltration: The speaker reports injecting Vilon directly into the dorsal aspect of her foot to treat self-diagnosed plantar fasciitis, claiming localized pain reduction within 15 minutes.
  • Dosing Structure Disparity: Unlike the typical continuous 8-week cycles of standard peptides, the speaker outlines a “bioregulator protocol” consisting of daily administration for 10 to 30 days, repeated only on a quarterly basis (every 3 months).
  • Absence of Mainstream Human Safety Data: Despite claims of a complete lack of toxicity or hormonal shifts, Vilon has not undergone rigorous Phase II or Phase III human clinical trials required to establish its safety profile or long-term adverse event rates in Western medicine (AMA, 2024).

IV. Actionable Protocol (Prioritized)

High Confidence Tier (Level A/B Evidence)

  • No Protocols Available: There are zero human protocols for Vilon backed by Level A (meta-analyses) or Level B (large-scale randomized controlled trials) evidence for injury healing, longevity, or autoimmune disease.
  • Note on Low-Level Human Data: A small-scale clinical evaluation observed that oral Vilon (Lys-Glu), administered twice daily for 30 days alongside standard eradication therapy, reduced subjective symptoms in patients with chronic atrophic gastritis and promoted gastric mucosa repair (Dipeptide in Atrophic Gastritis, 2020). However, this is isolated, low-powered data (Level C/D) and cannot be generalized as a high-confidence protocol.

Experimental Tier (Level C/D Evidence / Preclinical Models)

The following parameter ranges are derived strictly from gray-market longevity literature and historical Russian rodent models. They carry significant safety and purity uncertainties:

  • Subcutaneous Administration: Longevity literature sources describe protocols utilizing 1.0 mg to 2.0 mg injected subcutaneously once daily. The speaker outlines a split protocol of 1.0 mg localized to the injury site in the morning and 1.0 mg in the abdomen in the evening.
  • Cycle Duration: Administered continuously for 10 to 30 days.
  • Frequency: Repeated quarterly (once every 3 to 6 months), rather than run as a continuous, chronic cycle.
  • Alternative Low-Dose Protocol: Historical animal longevity studies utilized an equivalent low-dose approach of approximately 0.1 μg to 1.0 μg subcutaneously for 5 consecutive days per month (Medicalsparx Research Profile).

Red Flag Zone (Critical Safety and Translational Failures)

  • “Safety Data Absent” for Human Injection: Vilon is classified as a research chemical. It lacks United States Food and Drug Administration (FDA) approval, and the manufacturing quality control of online grey-market vendors is completely unregulated. Contamination with endotoxins, heavy metals, or structural isomers presents severe health risks (AMA, 2024).
  • Localized Foot Injections: The speaker’s protocol of injecting a research chemical into the highly complex, dense fascial architecture of the top of the foot for plantar fasciitis is clinically dangerous. It introduces significant risks of deep tissue infection, structural nerve damage, tendon rupture, and localized necrosis.
  • Unsubstantiated Medical Claims: Using Vilon to treat active autoimmune conditions (Hashimoto’s, Rheumatoid Arthritis) or substituting it for established medical therapies is highly dangerous. Modulating immune pathways with unapproved thymic derivatives without clinical supervision can theoretically exacerbate autoimmune flares or trigger unpredictable systemic immune responses.
  • Oncological Extrapolation: Extrapolating rodent data showing tumor reduction into a claim that Vilon can be used as a “supportive tool” for human cancer prevention is highly premature and scientifically invalid.